4.6 Review

Meibomian gland dysfunction and primary Sjogren's syndrome dry eye: a protocol for systematic review and meta-analysis

期刊

BMJ OPEN
卷 11, 期 12, 页码 -

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2020-048336

关键词

rheumatology; ophthalmology; protocols & guidelines; immunology

资金

  1. Science and Technology Development Fund of the Hospital of Chengdu University of Traditional Chinese Medicine [19LW19, 18MZ12]

向作者/读者索取更多资源

This study aims to investigate the association between MGD and SSDE, suggesting that SSDE is not merely an aqueous-deficient dry eye, but also influenced by factors such as MGD. No related systematic review and meta-analysis have been published on this topic.
Introduction Primary Sjogren's syndrome (pSS) is a systemic autoimmune disorder that primarily affects the exocrine glands such as the lacrimal and the salivary glands. Dry eye disease (DED) is one of the most prevalent manifestations of pSS and is usually classified into aqueous-deficient dry eye and evaporative dry eye. Sjogren's syndrome dry eye (SSDE) is generally described as aqueous-deficient dry eye. However, as the leading pathophysiological mechanism of evaporative dry eye, meibomian gland dysfunction (MGD) also has influence on SSDE, which has been shown in recent studies. We speculate that SSDE is more than just an aqueous-deficient dry eye. While no related systematic review and meta-analysis has been published, the present study is designed to derive a better understanding of the association between MGD and SSDE. Methods and analysis The Preferred Reporting items for Systematic Reviews and Meta-Analysis for Protocols 2015 statement was used to prepare this protocol. PubMed, Embase, Web of Science, Cochrane Database, China National Knowledge Infrastructure and Wan Fang Database will be searched from their inception to 31 October 2021, with restrictions to publications in English or Chinese. Two reviewers will independently carry out data extraction and quality assessment. The diagnosis of pSS will meet the standard diagnostic criteria, such as American College of Rheumatology/European League against Rheumatism Classification Criteria (ACR/EULAR) or American-European Consensus Group Classification criteria (AECG), and the definition of MGD and DED will differ between studies. The quality of included studies will be judged using the Newcastle-Ottawa Quality Scale. We will carry out this meta-analysis using RevMan V.5.4.1. The incidence of MGD in patients with SSDE will be indicated as OR with 95% CI. Ethics and dissemination Ethical approval is not required as this meta-analysis is performed based on published studies and does not involve human participants. The results will be published in a peer-reviewed journal. PROSPERO registration number CRD42021226017.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据